Published online Nov 15, 2026. doi: 10.4251/wjgo.122505
Revised: July 24, 2026
Accepted: September 18, 2026
Published online: November 15, 2026
Processing time: 198 Days and 18.4 Hours
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, making early detection of precancerous adenomas critical for effective prevention. The systemic immune-inflammation index (SII), derived from peri
To investigate the clinical utility of SII in screening for CRC and precancerous adenomas, and to evaluate its association with pathological features and prog
This retrospective study included 332 patients (141 with CRC, 191 with colorectal adenoma) who underwent colonoscopy between January 2019 and June 2025. Pe
SII was significantly higher in CRC than that in adenomas [712.76 (IQR: 435.87-1586.92) vs 347.56 (IQR: 256.05-471.03), P < 0.001]. The optimal SII cut-off for distinguishing CRC from adenoma was 480.326 [area under the curve (AUC) = 0.801, sensitivity 72.3%, specificity 76.1%]. Multivariate logistic regression confirmed that elevated SII [per 100-unit increase: Odds ratio (OR) = 1.195, 95% confidence interval: 1.101-1.298, P < 0.001], NLR (OR = 1.489, P < 0.001), PLR (OR = 1.009, P < 0.001), and CRP (OR = 1.069, P = 0.003) were independent risk factors for CRC after adjusting for age, hemoglobin, carcinoembryonic antigen, and fecal immunochemical test. For predicting lymph node meta
Elevated SII is an independent risk factor for CRC and may serve as a useful auxiliary screening marker. Preope
Core Tip: This retrospective study explored the clinical value of systemic immune-inflammation index (SII) screening and assessing colorectal adenoma and colorectal cancer (CRC). Receiver operating characteristic curve determined SII’s diag
- Citation: Xu J, Li SX. Exploring the role of the systemic immune-inflammation index in colorectal cancer: A study on screening and prognostic assessment. World J Gastrointest Oncol 2026; 18(11): 122505
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/122505.htm
- DOI: https://dx.doi.org/10.4251/wjgo.122505
Colorectal cancer (CRC) ranks among the most prevalent malignancies of the digestive system, representing a significant risk to public health and safety[1]. The existing theory suggests that the emergence and progression of CRC primarily adhere to the "adenoma-cancer" sequential theory, with 80%-90% of CRCs originate from precancerous lesions of the colon, and this cancerous process is generally believed to take 5-10 years[2]. Therefore, effective screening and early diagnosis of precancerous lesions and early-stage CRC are of great clinical importance for disease prevention and control[3]. There are many screening methods for CRC, with abdominal computed tomography and colonoscopy being the main examination methods. However, the detection rate depends on operator experience and there is a certain rate of missed diagnosis. In recent years, emerging detection methods have not fully developed and are expensive, including circulating tumor cells and circulating tumor DNA (ctDNA), in experimental technology, making it difficult to popularize and promote[4]. More and more studies have confirmed that serological indicators have good clinical application prospects in cancer screening, diagnosis, and prognosis evaluation. The systemic immune-inflammation index (SII) is a composite biomarker derived from peripheral platelet, neutrophil, and lymphocyte counts. Clinical studies have demonstrated that SII reflects the balance between systemic inflammation and immune surveillance, and has been associated with clinical outcomes in various malignancies[5]. Clinical data also indicates a link between SII levels and both the anti-tumor response as well as immune surveillance status in individuals with cancer[5]. Although several studies have reported the prognostic value of SII in CRC, its role in distinguishing CRC from precancerous adenomas—a clinically pivotal step in the adenoma-carcinoma sequence—has been less systematically evaluated. Unlike most previous studies that used heal
Therefore, this study collected clinical data from CRC patients and colorectal adenoma patients through retrospective research, examined the correlation between SII and clinical characteristics and CRC outcomes, explored the potential clinical significance of SII in screening and prognosis evaluation of colorectal precancerous lesions and CRC, and pro
Patients who underwent colonoscopy and were identified as having CRC or precancerous lesions between January 1, 2019 and June 30, 2025 were included in this study. Clinical data were retrospectively collected from the hospital's elec
Inclusion criteria: Patients with CRC or colorectal adenoma detected through a complete colonoscopy examination and pathology[6].
Exclusion criteria: (1) Incomplete clinical data; (2) Concurrent other malignancies; (3) Acute infectious diseases or chronic wasting diseases; (4) Current use of hormonal or immunosuppressive therapy; or (5) Antibiotic use within the past month (assessed by medical record review and confirmed by patient interview).
This retrospective study used the hospital's electronic medical record system to collect clinical data, including baseline characteristics, C-reactive protein (CRP), carcinoembryonic antigen (CEA), and routine blood test results. The PLR, NLR, along with SII were calculated separately. Follow-up was calculated from the date of surgery. Overall survival (OS) was defined as the time from surgery to death from any cause or last known follow-up. Follow-up data were obtained through outpatient clinic records and telephone interviews. No patients were lost to follow-up during the study period.
Given the retrospective and exploratory nature of this study, no formal a priori sample size calculation was performed. The sample size was determined by the availability of eligible patients during the study period. Two separate receiver operating characteristic (ROC) analyses were performed to determine SII cut-offs: (1) For distinguishing CRC from colorectal adenoma in the entire cohort (n = 332); and (2) For predicting lymph node metastasis in the surgical subgroup (n = 91). The optimal cut-off for each analysis was determined using the Youden index (maximum sensitivity + specificity - 1). Median (Q25, Q75) is used to describe the median and dispersion trend. Non-normal quantitative data are assessed through the rank sum test, while χ2 test facilitates comparisons between two distinct groups. Univariate logistic re
This research encompassed 332 participants, of whom 141 receiving a diagnosis of CRC. The results indicated notable differences in factors such as age, tumor location, fecal immunochemical test (FIT) results, fatty liver, cholesterol levels, triglyceride levels, hemoglobin levels, and CEA values between colorectal adenoma and CRC categories (P < 0.001; Table 1).
| Variables | Total (n = 332) | Colorectal cancer group (n = 141) | Colorectal adenoma group (n = 191) | Statistic | P value |
| Age (year) | 63.00 (54.00, 73.00) | 72.00 (62.50, 78.00) | 58.00 (51.00, 67.00) | Z = 8.843 | < 0.001 |
| Gender | χ2 = 0.365 | 0.546 | |||
| Male | 218 (65.66) | 90 (63.83) | 128 (67.02) | ||
| Female | 114 (34.34) | 51 (36.17) | 63 (32.98) | ||
| Position of the lesion | χ2 = 24.141 | < 0.001 | |||
| Rectum | 58 (17.47) | 37 (26.24) | 21 (10.99) | ||
| Left hemicolon | 149 (44.88) | 43 (30.50) | 106 (55.50) | ||
| Right hemicolon | 125 (37.65) | 61 (43.26) | 64 (33.51) | ||
| FIT | χ2 = 104.610 | < 0.001 | |||
| Negative | 181 (54.52) | 31 (21.99) | 150 (78.53) | ||
| Positive | 151 (45.48) | 110 (78.01) | 41 (21.47) | ||
| Fatty liver | χ2 = 30.521 | < 0.001 | |||
| No | 280 (84.34) | 137 (97.16) | 143 (74.87) | ||
| Yes | 52 (15.66) | 4 (2.84) | 48 (25.13) | ||
| CEA (ng/mL) | 2.04 (1.16, 3.71) | 3.57 (1.55, 11.53) | 1.72 (0.93, 2.47) | Z = 7.128 | < 0.001 |
| Hb (g/L) | 131.00 (117.00, 146.00) | 116.00 (92.50, 130.50) | 140.00 (129.50, 152.00) | Z = 10.261 | < 0.001 |
| TG (mmol/L) | 1.28 (0.91, 1.86) | 1.05 (0.82, 1.39) | 1.46 (1.11, 2.26) | Z = 6.498 | < 0.001 |
| TC (mmol/L) | 4.39 (3.80, 5.08) | 3.99 (3.41, 4.78) | 4.70 (4.12, 5.25) | Z = 5.846 | < 0.001 |
Compared with the colorectal adenoma group, the CRC group showed significantly higher median SII [712.76 (IQR: 435.87-1586.92) vs 347.56 (IQR: 256.05-471.03), P < 0.001], PLR [173.20 (IQR: 121.93-267.07) vs 103.91 (IQR: 85.18-125.13), P < 0.001], NLR [3.31 (IQR: 2.11-5.58) vs 1.73 (IQR: 1.31-2.30), P < 0.001], CRP [4.90 (IQR: 2.09-18.84) vs 1.15 (IQR: 0.56-4.75), P < 0.001], platelet count [233.00 (IQR: 183.00-302.00) vs 197.00 (IQR: 166.00-239.00), P < 0.001], and neutrophil count [4.40 (IQR: 3.40-6.43) vs 3.44 (IQR: 2.79-4.32), P < 0.001]. Conversely, lymphocyte count [1.30 (IQR: 0.92-1.67) vs 1.98 (IQR: 1.56-2.34), P < 0.001], albumin [40.00 (IQR: 36.95-43.35) vs 44.00 (IQR: 42.00-47.20), P < 0.001], and hemoglobin [116.00 (IQR: 92.50-130.50) vs 140.00 (IQR: 129.50-152.00), P < 0.001] were significantly lower in the CRC group. Additionally, the CRC group was older [72.00 (IQR: 62.50-78.00) vs 58.00 (IQR: 51.00-67.00), P < 0.001] and had higher CEA levels [3.57 (IQR: 1.55-11.53) vs 1.72 (IQR: 0.93-2.47), P < 0.001], but lower triglyceride [1.05 (IQR: 0.82-1.39) vs 1.46 (IQR: 1.11-2.26), P < 0.001] and cholesterol levels [3.99 (IQR: 3.41-4.78) vs 4.70 (IQR: 4.12-5.25), P < 0.001; Figure 1 and Table 2].
| Variables | Total (n = 332) | Colorectal cancer group | Colorectal adenoma group | Z value | P value |
| PLT (109/L) | 208.50 (170.00, 260.00) | 233.00 (183.00, 302.00) | 197.00 (166.00, 239.00) | 4.171 | < 0.001 |
| Neu (109/L) | 3.80 (2.97, 4.95) | 4.40 (3.40, 6.43) | 3.44 (2.79, 4.32) | 5.817 | < 0.001 |
| Lym (109/L) | 1.67 (1.28, 2.18) | 1.30 (0.92, 1.67) | 1.98 (1.56, 2.34) | 8.834 | < 0.001 |
| PLR | 120.48 (91.57, 169.64) | 173.20 (121.93, 267.07) | 103.91 (85.18, 125.13) | 9.832 | < 0.001 |
| NLR | 2.12 (1.50, 3.45) | 3.31 (2.11, 5.58) | 1.73 (1.31, 2.30) | 9.544 | < 0.001 |
| SII | 436.25 (288.84, 725.97) | 712.76 (435.87, 1586.92) | 347.56 (256.05, 471.03) | 9.450 | < 0.001 |
| CRP (mg/L) | 2.51 (0.75, 6.27) | 4.90 (2.09, 18.84) | 1.15 (0.56, 4.75) | 7.339 | < 0.001 |
| ALB (g/L) | 42.90 (39.63, 45.80) | 40.00 (36.95, 43.35) | 44.00 (42.00, 47.20) | 8.159 | < 0.001 |
Univariate analysis showed no statistical difference in patient gender when comparing the CRC group to those with colorectal adenoma groups; age, lesion location, FIT, fatty liver, CEA, hemoglobin, platelets, neutrophils, lymphocytes, PLR, NLR, SII, albumin, triglycerides, cholesterol, and CRP were all significantly associated with the two groups (Table 3). Regarding the interpretation of odds ratios (ORs) presented in Table 3, the outcome variable in the logistic regression was coded as adenoma = 1 and CRC = 0. Therefore, OR less than 1 indicate a higher probability of CRC, while OR greater than 1 indicate a higher probability of adenoma. For example, the OR of 0.997 for SII corresponds to an OR of approximately 1.003 for predicting CRC per unit increase in SII. The OR of 11.497 for fatty liver indicates a strong association with adenoma, which is consistent with the higher prevalence of fatty liver in the adenoma group shown in Table 1. Readers should be aware of this coding when interpreting Table 3.
| Variables | β | SE | Wald | P value | OR (95%CI) |
| Age | -0.096 | 0.012 | 59.262 | < 0.001 | 0.908 (0.886-0.931) |
| Gender | |||||
| Male | Reference | ||||
| Female | -0.141 | 0.233 | 0.365 | 0.546 | 0.869 (0.550-1.372) |
| Position of the lesion | |||||
| Rectum | Reference | ||||
| Left hemicolon | 1.469 | 0.328 | 20.095 | < 0.001 | 4.343 (2.285-8.255) |
| Right hemicolon | 0.614 | 0.327 | 3.539 | 0.060 | 1.849 (0.975-3.506) |
| FIT | |||||
| Negative | Reference | ||||
| Positive | -2.564 | 0.269 | 90.764 | < 0.001 | 0.077 (0.045-0.131) |
| Fatty liver | |||||
| No | Reference | ||||
| Yes | 2.442 | 0.534 | 20.916 | < 0.001 | 11.497 (4.037-32.740) |
| CEA | -0.369 | 0.068 | 29.168 | < 0.001 | 0.691 (0.605-0.791) |
| PLT | -0.008 | 0.002 | 23.562 | < 0.001 | 0.992 (0.989-0.995) |
| Neu | -0.389 | 0.070 | 31.103 | < 0.001 | 0.677 (0.591-0.777) |
| Lym | 1.810 | 0.240 | 56.971 | < 0.001 | 6.109 (3.819-9.775) |
| PLR | -0.024 | 0.003 | 55.659 | < 0.001 | 0.976 (0.970-0.983) |
| NLR | -0.671 | 0.104 | 41.786 | < 0.001 | 0.511 (0.417-0.627) |
| SII | -0.003 | 0.000 | 42.177 | < 0.001 | 0.997 (0.996-0.998) |
| ALB | 0.226 | 0.031 | 51.568 | < 0.001 | 1.253 (1.178-1.333) |
| TG | 1.074 | 0.197 | 29.566 | < 0.001 | 2.926 (1.987-4.309) |
| TC | 0.619 | 0.123 | 25.330 | < 0.001 | 1.858 (1.460-2.364) |
| CRP | -0.081 | 0.016 | 24.199 | < 0.001 | 0.922 (0.893-0.953) |
To further identify independent risk factors for CRC, variables with P < 0.1 in univariate analysis were entered into a forward stepwise multivariate logistic regression model. Due to collinearity among inflammatory indices (PLR, NLR, and SII), separate models were constructed for each index. After adjusting for age, hemoglobin, CEA, and FIT positivity, SII remained significantly associated with CRC [per 100-unit increase: OR = 1.195, 95% confidence interval (95%CI): 1.101-1.298, P < 0.001]. NLR (OR = 1.489, 95%CI: 1.232-1.800, P < 0.001), PLR (OR = 1.009, 95%CI: 1.004-1.014, P < 0.001), and CRP (OR = 1.069, 95%CI: 1.023-1.118, P = 0.003) also remained independent predictors in their respective models. These results confirm that elevated SII is an independent risk factor for CRC (Supplementary Table 1).
ROC curve in diagnosing CRC
Using the colorectal adenoma group as the control, ROC curves for diagnosing CRC were constructed based on CRP, PLR, NLR, and SII. CRP, PLR, NLR, and SII showed diagnostic value for distinguishing CRC from adenoma (Figure 2 and Table 4).
| AUC (95%CI) | P value | Sensitivity | Specificity | Youden index | Cut-off value | |
| CRP | 0.738 (0.683, 0.793) | < 0.001 | 0.796 | 0.601 | 0.397 | 1.675 |
| PLR | 0.811 (0.760, 0.862) | < 0.001 | 0.657 | 0.904 | 0.561 | 148.3891 |
| NLR | 0.802 (0.753, 0.851) | < 0.001 | 0.650 | 0.819 | 0.469 | 2.4854 |
| SII | 0.801 (0.751, 0.850) | < 0.001 | 0.723 | 0.761 | 0.484 | 480.3264 |
Among CRC patients, 91 underwent radical surgery, and their postoperative pathological characteristics were further analyzed. Based on the cut-off value, the preoperative low SII group was defined as ≤ 411.93, and the high SII category was defined as > 411.93. When comparing the two categories, the preoperative high SII group of patients with CRC showed statistically significant differences in stages T1-2 vs T3-4, N0 vs N1-2, as well as in vascular/neural invasion (P < 0.05; Table 5).
| Variables | Total (n = 91) | SII low value group | SII high value group | χ2 value | P value |
| Position of the lesion | 3.199 | 0.202 | |||
| Rectum | 25 (27.47) | 11 (35.48) | 14 (23.33) | ||
| Left hemicolon | 25 (27.47) | 10 (32.26) | 15 (25.00) | ||
| Right hemicolon | 41 (45.05) | 10 (32.26) | 31 (51.67) | ||
| Lesion size (cm) | 0.691 | 0.406 | |||
| ≤ 3 | 19 (20.88) | 8 (25.81) | 11 (18.33) | ||
| > 3 | 72 (79.12) | 23 (74.19) | 49 (81.67) | ||
| Pathological differentiation degree | - | 0.736 | |||
| Poorly differentiated adenocarcinoma | 22 (24.18) | 6 (19.35) | 16 (26.67) | ||
| Moderately differentiated adenocarcinoma | 64 (70.33) | 23 (74.19) | 41 (68.33) | ||
| Well differentiated adenocarcinoma | 5 (5.49) | 2 (6.45) | 3 (5.00) | ||
| T | 6.910 | 0.009 | |||
| T1-2 | 23 (25.27) | 13 (41.94) | 10 (16.67) | ||
| T3-4 | 68 (74.73) | 18 (58.06) | 50 (83.33) | ||
| N | 4.919 | 0.027 | |||
| N0 | 53 (58.24) | 23 (74.19) | 30 (50.00) | ||
| N1-2 | 38 (41.76) | 8 (25.81) | 30 (50.00) | ||
| Cut edge | - | 0.546 | |||
| Negative | 89 (97.80) | 31 (100.00) | 58 (96.67) | ||
| Positive | 2 (2.20) | 0 (0.00) | 2 (3.33) | ||
| Vascular nerve infiltration | 4.251 | 0.039 | |||
| No | 51 (56.04) | 22 (70.97) | 29 (48.33) | ||
| Yes | 40 (43.96) | 9 (29.03) | 31 (51.67) |
During the follow-up, 83 survived while 8 died, including 4 cases of liver metastasis. Among the 8 deceased patients,2 had liver metastasis. A notable difference in OS rates was observed between those with liver metastasis and those without (P = 0.037). The presence of liver metastasis following CRC surgery poses a risk for reduced survival duration (Table 6). The OS duration was less in the high SII group (P = 0.07), although this did not reach statistical significance.
| Variables | Total (n = 91) | Survival (n = 83) | Death (n = 8) | χ2 value | P value |
| Gender | 0.000 | 1.000 | |||
| Male | 56 (61.54) | 51 (61.45) | 5 (62.50) | ||
| Female | 35 (38.46) | 32 (38.55) | 3 (37.50) | ||
| Age (year) | 1.681 | 0.195 | |||
| ≤ 60 | 23 (25.27) | 23 (27.71) | 0 (0.00) | ||
| > 60 | 68 (74.73) | 60 (72.29) | 8 (100.00) | ||
| Position of the lesion | - | 0.583 | |||
| Rectum | 25 (27.47) | 24 (28.92) | 1 (12.50) | ||
| Left hemicolon | 25 (27.47) | 23 (27.71) | 2 (25.00) | ||
| Right hemicolon | 41 (45.05) | 36 (43.37) | 5 (62.50) | ||
| Lesion size (cm) | 0.024 | 0.877 | |||
| ≤ 3 | 19 (20.88) | 18 (21.69) | 1 (12.50) | ||
| > 3 | 72 (79.12) | 65 (78.31) | 7 (87.50) | ||
| Pathological differentiation degree | - | 0.497 | |||
| Poorly differentiated adenocarcinoma | 22 (24.18) | 20 (24.10) | 2 (25.00) | ||
| Moderately differentiated adenocarcinoma | 64 (70.33) | 59 (71.08) | 5 (62.50) | ||
| Well differentiated adenocarcinoma | 5 (5.49) | 4 (4.82) | 1 (12.50) | ||
| T | 0.000 | 1.000 | |||
| T1-2 | 23 (25.27) | 21 (25.30) | 2 (25.00) | ||
| T3-4 | 68 (74.73) | 62 (74.70) | 6 (75.00) | ||
| N | 0.014 | 0.905 | |||
| N0 | 53 (58.24) | 49 (59.04) | 4 (50.00) | ||
| N1-2 | 38 (41.76) | 34 (40.96) | 4 (50.00) | ||
| Cut edge | - | 1.000 | |||
| Negative | 89 (97.80) | 81 (97.59) | 8 (100.00) | ||
| Positive | 2 (2.20) | 2 (2.41) | 0 (0.00) | ||
| Vascular nerve infiltration | 0.000 | 0.990 | |||
| No | 51 (56.04) | 46 (55.42) | 5 (62.50) | ||
| Yes | 40 (43.96) | 37 (44.58) | 3 (37.50) | ||
| Postoperative liver metastasis | - | 0.037 | |||
| No | 87 (95.60) | 81 (97.59) | 6 (75.00) | ||
| Yes | 4 (4.40) | 2 (2.41) | 2 (25.00) | ||
| PLT | 0.001 | 0.975 | |||
| Low value | 63 (69.23) | 58 (69.88) | 5 (62.50) | ||
| High value | 28 (30.77) | 25 (30.12) | 3 (37.50) | ||
| Neu | 1.802 | 0.179 | |||
| Low value | 49 (53.85) | 47 (56.63) | 2 (25.00) | ||
| High value | 42 (46.15) | 36 (43.37) | 6 (75.00) | ||
| Lym | - | 1.000 | |||
| Low value | 1 (1.10) | 1 (1.20) | 0 (0.00) | ||
| High value | 90 (98.90) | 82 (98.80) | 8 (100.00) | ||
| PLR | 2.869 | 0.090 | |||
| Low value | 54 (59.34) | 52 (62.65) | 2 (25.00) | ||
| High value | 37 (40.66) | 31 (37.35) | 6 (75.00) | ||
| NLR | 3.216 | 0.073 | |||
| Low value | 32 (35.16) | 32 (38.55) | 0 (0.00) | ||
| High value | 59 (64.84) | 51 (61.45) | 8 (100.00) | ||
| SII | 1.681 | 0.195 | |||
| Low value | 23 (25.27) | 23 (27.71) | 0 (0.00) | ||
| High value | 68 (74.73) | 60 (72.29) | 8 (100.00) | ||
| CRP | 0.571 | 0.450 | |||
| Low value | 72 (79.12) | 67 (80.72) | 5 (62.50) | ||
| High value | 19 (20.88) | 16 (19.28) | 3 (37.50) |
Unlike most previous studies that compared CRC patients with healthy controls, the present study used colorectal ade
Inflammation is closely linked to tumorigenesis. Inflammation indicators are significant in the processes of screening, diagnosis, and prognostic assessment of tumors[7]. Systemic inflammation and immune dysregulation have been increa
The literature on SII and tumors covers different types of tumors[10-12]. The prognostic and diagnostic value of SII has been particularly well-documented in gastrointestinal malignancies, where systemic inflammation plays a central role in tumor development and progression[13]. Clinical studies have shown that SII is effective in distinguishing CRC from other colorectal lesions in individuals who have positive results on fecal occult blood test (FOBT)[14]. SII is utilized for screening CRC and precancerous lesions, which may help endoscopists make preliminary judgments on the pathological nature of lesions during colonoscopy[15]. This study used colorectal adenomas as the control group and colon cancer group as the observation group. There exists a significant difference in age, lesion location, fecal occult blood, fatty liver, CEA, hemoglobin, triglycerides, cholesterol, neutrophils, platelets, lymphocytes, albumin, PLR, NLR, SII, and CRP be
Taking the colon adenoma group as the control group, PLR, NLR, SII, and CRP were selected to further plot the ROC curve. The ROC curve area under SII for diagnosing CRC is 0.801, with a critical value of 480.326. Its sensitivity and specificity for diagnosing CRC are 72.3% and 76.1%, respectively. Sumimoto et al[16] utilized the JNET classification cri
The clinical research findings on the link between SII and postoperative pathological features in tumor patients are inconsistent. A meta-analysis investigated the connection between SII and the pathological characteristics and prognosis of cholangiocarcinoma. An increased SII was linked to lymph node metastasis (OR = 1.44, 95%CI: 1.18-1.76; P < 0.001), TNM staging (OR = 1.49, 95%CI: 1.05-2.13; P = 0.028), and vascular invasion (OR = 1.39, 95%CI: 1.05-2.13; P = 0.028); there was no correlation between elevated SII and factors such as gender or tumor differentiation. The results confirmed that high SII levels correlate with unfavorable prognosis and malignant characteristics among cholangiocarcinoma patients[19]. A retrospective clinical study on ovarian serous cystadenoma and ovarian serous cystadenocarcinoma indicated a correlation between SII and factors such as differentiation degree, lymph node metastasis, and serum CA125 levels. The results of the Spearman correlation analysis indicate a positive relationship between SII and lymph node metastasis (r = 0.689, P < 0.001)[20]. This research identified that the most effective predictive value of SII for lymph node metastasis is 411.93. Compared with patients with lower SII scores, significant differences were noted between T1-2 and T3-4 stages (P = 0.009), as well as between N0 and N1-2 stages (P = 0.027), in addition to vascular and neural invasion (P = 0.039).
A meta-analysis incorporating 9 clinical studies with 2,365 patients diagnosed with pancreatic cancer demonstrated a negative correlation between SII and OS [hazard ratio (HR) = 1.50, 95%CI: 1.15-1.96, P = 0.002], recurrence-free survival (RFS)/progression-free survival/disease progression-free survival (DFS; HR = 1.52, 95%CI: 1.01-2.28, P = 0.045), and chemotherapy-free survival (HR = 2.60, 95%CI: 1.65-4.09, P < 0.001).Research has confirmed that high SII serves as a crucial prognostic indicator for both short- and long-term survival outcomes among individuals having pancreatic cancer[21]. Clinical research indicates that the ideal cutoff for SII to predict OS following gastric cancer surgery is 395. The five-year OS rate for patients with SII ≥ 395 was recorded at 80.0%, which was markedly lower compared to the 92.7% rate in those with SII < 395 (P < 0.001). Through analysis, SII ≥ 395 (95%CI: 1.49-6.39; P = 0.001), cardiac disease (95%CI: 1.07-4.07), pT4 (95%CI: 2.44-8.14), and positive peritoneal metastasis (PN+; 95%CI: 2.10-7.93) were independent factors contributing to worsening OS. Furthermore, the peritoneal metastasis rate was greater in the high SII cohort compared to the low SII cohort (P = 0.028)[22]. A retrospective analysis involving 1383 individuals who underwent radical resection for CRC identified a cutoff value of 340 for SII; those with low SII levels experienced improved OS and DFS (P < 0.05). Multivariate analysis suggest that SII serves as an independent predictor of OS and DFS. The AUC for SII (0.707) surpasses that of NLR and PLR[23]. The OS duration was shorter in the high SII group compared with the low SII group, although this difference did not reach statistical significance (log-rank P = 0.077). Notably, no deaths occurred in the low SII group (n = 23), while 8 deaths occurred in the high SII group (n = 68), representing an absolute mortality difference of 11.8% (0% vs 11.8%). While the P value is not formally significant, this absolute difference may be clinically meaningful and warrants investigation in larger, adequately powered cohorts. The lack of statistical significance may be attributable to the small sample size and limited number of events (n = 8), which substantially reduces the power of the survival analysis.
Existing research has confirmed that 60%-70% of individuals died from advanced CRC exhibit liver metastasis, which is the leading cause of mortality among these patients. A retrospective clinical investigation involving 182 patients with CRC who underwent surgical resection utilized the ROC curve to evaluate the predictive capacity of the SII for liver metastasis following surgery. Analyses conducted both univariately and multivariately indicated that SII is an indepen
This study carried out a retrospective analysis to collect clinical data from CRC and colorectal adenoma patients. The cut-off value for SII assisted diagnosis of CRC and precancerous lesions is 480.326. Preoperative high SII is an indepen
Several limitations of this study should be acknowledged. First, this was a retrospective, single-center study with a relatively small sample size, which limits the generalizability of our findings. Second, the logistic regression analysis was limited to univariate models; multivariate analysis adjusting for potential confounders (e.g., age, tumor stage, comorbi
Elevated SII is an independent risk factor for CRC and may serve as a useful auxiliary screening marker. Preoperative SII correlates with aggressive pathological features, but its prognostic value requires validation in larger prospective cohorts with longer follow-up.
| 1. | Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-263. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 16785] [Cited by in RCA: 18093] [Article Influence: 9046.5] [Reference Citation Analysis (55)] |
| 2. | Morson B. President's address. The polyp-cancer sequence in the large bowel. Proc R Soc Med. 1974;67:451-457. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 197] [Cited by in RCA: 146] [Article Influence: 2.8] [Reference Citation Analysis (5)] |
| 3. | Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, Nowacki MP, Butruk E. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006;355:1863-1872. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 595] [Cited by in RCA: 540] [Article Influence: 27.0] [Reference Citation Analysis (4)] |
| 4. | Ma X, Chen Y, Tang W, Bao H, Mo S, Liu R, Wu S, Bao H, Li Y, Zhang L, Wu X, Cai S, Shao Y, Liu F, Peng J. Multi-dimensional fragmentomic assay for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma. J Hematol Oncol. 2021;14:175. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 2] [Cited by in RCA: 46] [Article Influence: 9.2] [Reference Citation Analysis (0)] |
| 5. | Lolli C, Basso U, Derosa L, Scarpi E, Sava T, Santoni M, Crabb SJ, Massari F, Aieta M, Conteduca V, Maruzzo M, La Russa F, Wheater M, Berardi R, Galli L, De Giorgi U. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget. 2016;7:54564-54571. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 107] [Cited by in RCA: 126] [Article Influence: 12.6] [Reference Citation Analysis (5)] |
| 6. | Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR. AJCC Cancer Staging Manual. 8th ed. New York: Springer, 2017. |
| 7. | Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? Nat Rev Clin Oncol. 2021;18:261-279. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 329] [Cited by in RCA: 287] [Article Influence: 57.4] [Reference Citation Analysis (5)] |
| 8. | Picca A, Calvani R, Coelho-Junior HJ, Marzetti E. Cell Death and Inflammation: The Role of Mitochondria in Health and Disease. Cells. 2021;10:537. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 33] [Cited by in RCA: 160] [Article Influence: 32.0] [Reference Citation Analysis (2)] |
| 9. | Okada F, Izutsu R, Goto K, Osaki M. Inflammation-Related Carcinogenesis: Lessons from Animal Models to Clinical Aspects. Cancers (Basel). 2021;13:921. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 6] [Cited by in RCA: 24] [Article Influence: 4.8] [Reference Citation Analysis (5)] |
| 10. | Li Y, Luo H, Ye B, Zhang K, Liu C, Zu R, Ni S, He Q, Rao L, Wang Q, Wang D. Prognostic value of nutritional and inflammatory indicators in females with esophageal squamous cell cancer: A propensity score matching study. Front Genet. 2022;13:1026685. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 2] [Cited by in RCA: 3] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
| 11. | Yang Z, Zhang J, Lu Y, Xu Q, Tang B, Wang Q, Zhang W, Chen S, Lu L, Chen X. Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolization. Oncotarget. 2015;6:43090-43098. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 58] [Cited by in RCA: 66] [Article Influence: 6.0] [Reference Citation Analysis (1)] |
| 12. | Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer. Tohoku J Exp Med. 2015;236:297-304. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 258] [Cited by in RCA: 252] [Article Influence: 22.9] [Reference Citation Analysis (1)] |
| 13. | Alshammary RAA, Alshammary AG, Hameed WM, Al-Karawi AS. Multisystem effects of obesity: dysregulation of leptin, thyroid hormones, autoantibodies, immune and neurological responses. Egypt J Immunol. 2025;32:101-109. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 14. | Hasirci I, Şahin A. Importance of the neutrophil-lymphocyte ratio and systemic immune-inflammation index in predicting colorectal pathologies in fecal occult blood-positive patients. J Clin Lab Anal. 2023;37:e24878. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 7] [Reference Citation Analysis (0)] |
| 15. | Feng Z, Lin H, Yang X, Cao S, Gu X, Zhang Z, Deng W. Diagnostic Value of Inflammation-Related Indicators in Distinguishing Early Colon Cancer and Adenomatous Polyps. Cancer Control. 2023;30:10732748231180745. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 12] [Cited by in RCA: 19] [Article Influence: 6.3] [Reference Citation Analysis (1)] |
| 16. | Sumimoto K, Tanaka S, Shigita K, Hirano D, Tamaru Y, Ninomiya Y, Asayama N, Hayashi N, Oka S, Arihiro K, Yoshihara M, Chayama K. Clinical impact and characteristics of the narrow-band imaging magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team. Gastrointest Endosc. 2017;85:816-821. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 120] [Cited by in RCA: 119] [Article Influence: 13.2] [Reference Citation Analysis (3)] |
| 17. | Wang Y, Li WK, Su JY, Wang YD, Wu J. [Application value of systemic immune-inflammation index in the screening of early colorectal cancer and precancerous lesions]. Journal of Capital Medical University. 2022;43:760-766. [DOI] [Full Text] |
| 18. | Jin P, Kang Q, Wang X, Yang L, Yu Y, Li N, He YQ, Han X, Hang J, Zhang J, Song L, Han Y, Sheng JQ. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol. 2015;30:830-833. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 124] [Cited by in RCA: 121] [Article Influence: 11.0] [Reference Citation Analysis (4)] |
| 19. | Peng X, Wang X, Hua L, Yang R. Prognostic and Clinical Value of the Systemic Immune-Inflammation Index in Biliary Tract Cancer: A Meta-Analysis. J Immunol Res. 2022;2022:6988489. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 2] [Cited by in RCA: 25] [Article Influence: 6.3] [Reference Citation Analysis (0)] |
| 20. | Chen Y, Yuan L, Meng J, Luo Z, Gong L. Correlation of cell cycle-related kinase and SII with FIGO stage, lymph node metastasis, and prognosis of serous ovarian cancer. Indian J Cancer. 2025;62:273-280. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 21. | Shui Y, Li M, Su J, Chen M, Gu X, Guo W. Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2,365 patients. Aging (Albany NY). 2021;13:20585-20597. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 21] [Cited by in RCA: 48] [Article Influence: 9.6] [Reference Citation Analysis (1)] |
| 22. | Inoue H, Kosuga T, Kubota T, Konishi H, Shiozaki A, Okamoto K, Fujiwara H, Otsuji E. Significance of a preoperative systemic immune-inflammation index as a predictor of postoperative survival outcomes in gastric cancer. World J Surg Oncol. 2021;19:173. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 11] [Cited by in RCA: 32] [Article Influence: 6.4] [Reference Citation Analysis (4)] |
| 23. | Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, Chen CQ, He YL, Cai SR. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23:6261-6272. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in CrossRef: 618] [Cited by in RCA: 572] [Article Influence: 63.6] [Reference Citation Analysis (16)] |
| 24. | Lu Y, Xin D, Wang F. Predictive Significance Of Preoperative Systemic Immune-Inflammation Index Determination In Postoperative Liver Metastasis Of Colorectal Cancer. Onco Targets Ther. 2019;12:7791-7799. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 14] [Cited by in RCA: 32] [Article Influence: 4.6] [Reference Citation Analysis (1)] |